Dr. Pamela Nathan DHM L.Ac. has been delivering health to your front door since 1998. Happy patients in over 78 countries. Want an Appointment? Book Now

Free Shipping Over $69**

Shopping Cart

Your cart is currently empty.

Visbiome Probiotic Launched by Exegi Pharma

Visbiome™ Probiotic is Launched by ExeGi Pharma

The De Simone Formulation that has been extensively studied is Now Available

  On Feb 1 2016 PRNewswire-USNewswire published a press release to announce the launch of the new probiotic formulation, Visbiome™ by ExeGi Pharma, LLC

The press release states that “Visbiome contains the pioneering probiotic blend developed by Professor Claudio De Simone, M.D., Ph.D. (the “De Simone Formulation”), and it has the same strains, in the same concentrations and proportions, and is therapeutically equivalent to the VSL#3® probiotic blend produced before January 31, 2016. “

Visbiome is regarded as a medical food, and delivers anti-inflammatory probiotic bacteria in high concentrations in the digestive tract which normalizes the gut flora and provides sustained relief from symptoms of many gastroenterology type conditions which include ulcerative colitis, chronic pouchitis as well as irritable bowel syndrome (IBS).

Dr De Simone, chief medical officer of ExeGi Pharma. writes, “More than 20 years ago, I created my probiotic formulation with the aim of helping patients manage complex conditions and support a healthy microbiome, The benefits of this formulation have been demonstrated in rigorous research again and again, and I am pleased to partner with ExeGi Pharma to ensure continued access to the probiotic blend that patients and their healthcare professionals trust.”

Why is Visbiome so Special?

The press release goes on to explain that the De Simone Formulation is one of the few probiotic blends that has undergone rigorous double-blind, placebo-controlled scientific trials, tested in over 60 peer-reviewed studies.

Today, researchers continue to investigate the possible benefits of the De Simone Formulation in more than 20 trials around the globe. In fact, Visbiome will be the subject of a new clinical trial that is funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) to look at its therapeutic impact on people who have been diagnosed with HIV.

The press release explains that Professor De Simone initially partnered with VSL Pharmaceuticals, Inc. to produce and market his proprietary blend of probiotic strains under the designation “VSL#3,” which is a registered trademark owned by VSL Pharmaceuticals, Inc.

However, Professor De Simone is now collaborating exclusively with ExeGi Pharma to produce Visbiome. The license agreement between Professor De Simone and VSL Pharmaceuticals, Inc., which provided VSL Pharmaceuticals, Inc. the rights to market the De Simone Formulation using the “VSL#3” trademark, expired on January 31, 2016.

Martin Floch, M.D. is the clinical professor of medicine at Yale and editor-in-chief of the Journal of Clinical Gastroenterology. He says, “In my clinical practice, I’ve seen first-hand how the De Simone Formulation has helped my patients achieve stability in their conditions. It’s so important that they can continue to access the formulation that we both trust and that’s yielded tangible results.”

ExeGi has developed important product support features In launching Visbiome, This includes using capsules packaged in state-of-the-art Active-Vials, which ensure minimal moisture intrusion and enhanced product potency.

Claudio Fiocchi, M.D., an international authority in the field of inflammatory bowel disease (IBD) and professor of molecular medicine, Lerner College of Medicine and Department of Gastroenterology & Hepatology at the Cleveland Clinic Foundation is another fan of Dr De Simone’s formula. He says,. “Professor De Simone’s commitment to maintaining the integrity of his blend means that the known therapeutic effects of his original probiotic formulation will continue to be available to patients with a vast range of gastrointestinal ailments.”

Here are the details about Visbiome™

  • Visbiome™ is a probiotic consisting of eight strains of live, freeze-dried lactic acid bacteria.
  • Data show that the De Simone Formulation, now found in Visbiome, is effective in the dietary management of ulcerative colitis, pouchitis and irritable bowel syndrome (IBS).
  • The formulation that makes up Visbiome is currently being investigated in more than 20 trials around the globe.
  • Visbiome is manufactured exclusively for ExeGi Pharma, LLC and is not affiliated with, endorsed by, or distributed by VSL Pharmaceuticals, Inc.
  • Visbiome is available in capsules (122.5 billion strains per capsules) as well as regular and unflavored packets (450 billion strains each packet)

More About ExeGi Pharma

ExeGi Pharma, LLC is a biotechnology company that focuse on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi’s team leverages the growing advances in the field of microbiome science to deliver novel clinically supported live biotherapeutic and probiotic treatments for a wide variety of unmet medical needs. ExeGi is not affiliated with VSL Pharmaceuticals, Inc.

1 VSL#3 is a registered trademark of VSL#3 Pharmaceuticals, Inc. and is manufactured exclusively for VSL Pharmaceuticals, Inc. Visbiome is manufactured exclusively for ExeGi Pharma, LLC and is not affiliated with, endorsed by, or distributed by VSL Pharmaceuticals, Inc.

Copyright © 2018 Ecology Health Center / Crohns.net - HealthyLifeUSA.